Department of Periodontology, Bolu Abant Izzet Baysal University, Bolu, Turkey.
Department of Cardiology, Bolu Abant Izzet Baysal University, Bolu, Turkey.
Oral Dis. 2021 Jul;27(5):1313-1319. doi: 10.1111/odi.13655. Epub 2020 Oct 21.
The purpose of this study was to evaluate the occurrence rate of drug-induced gingival overgrowth (DIGO) in patients treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and calcium channel blockers (CCBs) such as amlodipine, lercanidipine, and benidipine, as well as to assess the relationship of those mentioned above with medication variables and oral hygiene.
Sociodemographic details, DIGO, and clinical periodontal parameters were obtained from one hundred and thirty-one patients receiving ACE inhibitors, ARBs, and CCBs for a period of at least 2 years.
The occurrence rate of DIGO was 19.6% in patients using CCB, 12.5% in the ARB group, and 7.5% in the ACE inhibitor group. In a subgroup analysis of CCBs, DIGO was found to be 31.8% in the amlodipine group, 13.3% in the lercanidipine group, and 7.1% in the benidipine group. While there was a significant relationship between amlodipine drug dosage and DIGO, no association was found between the duration of therapy and DIGO in all CCB subgroups.
There was no difference between the groups in terms of DIGO. Duration of therapy and drug dosage did not affect the severity of DIGO in both ACE inhibitors and ARB groups.
本研究旨在评估血管紧张素转换酶(ACE)抑制剂、血管紧张素受体阻滞剂(ARB)和钙通道阻滞剂(CCB)如氨氯地平、乐卡地平、贝尼地平治疗患者中药物诱导性牙龈增生(DIGO)的发生率,并评估上述因素与药物变量和口腔卫生的关系。
从 131 名接受 ACE 抑制剂、ARB 和 CCB 治疗至少 2 年的患者中获取人口统计学资料、DIGO 和临床牙周参数。
使用 CCB 的患者中 DIGO 的发生率为 19.6%,ARB 组为 12.5%,ACE 抑制剂组为 7.5%。在 CCB 的亚组分析中,DIGO 在氨氯地平组为 31.8%,乐卡地平组为 13.3%,贝尼地平组为 7.1%。虽然氨氯地平药物剂量与 DIGO 之间存在显著关系,但在所有 CCB 亚组中,治疗持续时间与 DIGO 之间均无关联。
各组之间 DIGO 无差异。治疗持续时间和药物剂量均不影响 ACE 抑制剂和 ARB 组中 DIGO 的严重程度。